CXCL8 and acute myeloid leukemia: U2AF1S34F predisposes to increased translation of interleukin 8, upregulating the inflammatory response and correlating with a higher incidence of relapsed or refractory AML in humans; blocking interleukin 8 led to tumor burden reduction in mice [44].